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Objectives: Hospital readmission has been an important issue in patients with 
chronic obstructive pulmonary disease (COPD), as it reflects exacerbation of the 
disease and quality of medical care, and incurs high medical expenditures. This 
study aimed to examine pattern and economic burden of readmission, and iden-
tify factors associated with risk of readmission in patients hospitalized for COPD 
in Taiwan. MethOds: The National Health Insurance claims database of a rep-
resentative sample (two million subjects) of Taiwanese population in 2005 was 
adopted for this study. Adult individuals who were discharged from acute hospitals 
for COPD in 2005 were selected and their readmission pattern one-year after dis-
charge were examined. Cox proportional hazards regression models were adopted 
to identify factors associated with risk of readmission. Results: The majority of 
the subjects was male and aged older than 65 years old. The 30-day, 3-month and 
one-year all-cause readmission rates were 28%, 46%, and 69%, respectively. The 
30-day, 3-month and one-year COPD-specific readmission rates were 10%, 17%, 
and 31%, respectively. Approximately one-fourth of the subjects were readmitted 
more than twice during the follow-up. COPD, pneumonia, and respiratory fail-
ure/insufficiency/arrest were the top three most frequent causes for readmission 
during 30 days, 3 months, or one year after discharge. In the one-yar follow-up, 
hospital readmission accounted for 73% of total healthcare expenditures. Gender, 
previous hospitalization history, comorbidities, and length of stay and hospital 
accreditation level of the index hospitalization were associated with risk of all-
cause readmission. Gender, previous hospitalization history, and length of stay and 
hospital accreditation level of the index hospitalization were associated with risk 
of COPD-specific readmission. cOnclusiOns: This study identified patterns and 
causes of short-term and long-term readmission, and factors associated with risk 
of readmission in patients hospitalized for COPD. The information is of importance 
for planning interventions to reduce hospital readmission rate.
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Objectives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting 
beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was 
developed to assess the budget impact of switching adult patients with persistent 
asthma and chronic obstructive pulmonary disease (COPD) from market-leading 
DPIs in the Italy – budesonide/formoterol Turbohaler® and fluticasone/salmeterol 
Diskus® – to DuoResp® Spiromax®. The potential cost benefit of improved inhala-
tion technique due to the innovative characteristics of the Spiromax® inhaler was 
also investigated. MethOds: The eligible adult patient population was based on 
current confirmed Italian asthma and COPD diagnosis rates, with the proportion 
of patients receiving FDCs based on market research data. Costs of FDCs were 
taken from ”Farmadati Italia” database and costs of scheduled and unscheduled 
healthcare events were based on “Tariffario Regione Lombardia”, with the number 
of events estimated based on publically available UK sources. Frequency of poor 
inhalation technique, and the associated increased risk of unscheduled healthcare 
events, were taken from a large (n= 1,664) cross-sectional, Italian observational 
study. Reduction in the proportion of patients with poor inhalation technique with 
DuoResp® Spiromax® was based on assumption. Results: An estimated 196,419 
adult patients used budesonide/formoterol Turbohaler® and 505,564 fluticasone/
salmeterol Diskus® annually in Italy with 85,442 and 174,451 of these estimated 
to exhibit poor inhalation technique, respectively. Assuming a hypothetical uptake 
of DuoResp® Spiromax®reaching 10.1% in year 5 and assumed Italian prices, the 
model predicted drug cost savings totalling € 53.66 million. Furthermore, 33,948 
unscheduled healthcare events could be avoided due to the predicted improve-
ment in inhalation technique with DuoResp® Spiromax® compared with these 
DPIs, resulting in further savings of € 4.12 million. cOnclusiOns: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent dis-
ease with a significant economic burden to the UK National Health Service (NHS). 
NICE recommends maintenance treatment including inhaled bronchodilator 
medications, such as long-acting muscarinic antagonists (LAMAs) and long-acting 
beta-2-agonists (LABAs). The objective of this model was to quantify the budget 
impact to the NHS of switching patients with moderate to very severe COPD from 
tiotropium to tiotropium + olodaterol Respimat®, compared with remaining on 
tiotropium monotherapy. MethOds: The model used a deterministic individual-
level Markov approach to compare scenarios with and without the introduction of 
tiotropium + olodaterol Respimat®into the health economy. Patients progressed 
through the model based on their individual FEV1 values at baseline and their 
post-treatment FEV1 value over 5 years. Relative treatment effects (estimated from a 
adequate response. The aim of this study was to compare use of xanthines in the 
treatment of chronic respiratory diseases between Serbia and the Scandinavian 
countries in the period from 2004 to 2013. MethOds: The data on utilization of 
drugs for obstructive airway diseases (ATC group R03) during the ten-year period 
(2004-2013) were retrieved by a retrospective, observational, population-based study, 
from the Medicines and Medical Devices Agency of Serbia, Finnish Medicines Agency 
Fimea, Danish Statens Serum Institut and Norwegian Institute of Public Health. 
ATC/DDD methodology was applied and the results were expressed in defined 
daily doses per 1000 inhabitants per day (DID). Results: While the utilization of 
xanthines (R03DA) showed a significant tendency to decrease in all Scandinavian 
countries during the whole observed period of time (4.4-fold in Denmark, 3.46-fold 
in Norway and 2.38-fold in Finland), in Serbia on the other hand, xanthines rep-
resented the most used drugs in the R03 group, with no clear decrease tendency. 
In 2013, xanthines accounted for less than 2% of total use of drugs in R03 group 
in Finland, Norway and Denmark (1.25 DID, 0.61 DID and 0.50 DID, respectively), 
versus 26% (7.11 DID) in Serbia. cOnclusiOns: The large differences in utiliza-
tion of xanthines between Serbia and other observed countries may suggest con-
siderable lower number of exacerbations of COPD in the Scandinavian countries 
due to better control of chronic respiratory diseases. Acknowledgement: This 
work was supported by the Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina, project No. 114-451-2458/2011 
and by the Ministry of Education, Science and Technological Development, Republic 
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Objectives: A previous study was conducted in France, in 2013, to evaluate the 
physicians’ prescribing practices related to sore throat. Special attention was paid 
to the use of rapid diagnostic test (TROD). The present study aims at describing how 
sore throat is managed at the community pharmacy-level and at identifying the 
patients’ expectations concerning this condition. MethOds: This was a national 
observational study conducted in community pharmacies distributed around 
France. It included two components: a questionnaire for pharmacists, administered 
by phone, and a self-administered survey submitted to adult patients spontaneously 
consulting pharmacists for sore throat. For the patient population, the data collected 
consisted in demographics, severity of sore throat and expectations. The pharma-
cists were interviewed on the type of products and advice delivered. Results: A 
total of 167 pharmacies were included in the study and 1663 patient questionnaires 
were analyzed. Data collected revealed that most patients (72%) seek pharmacists’ 
advice for sore throat in the first 48 hours after onset and expect in priority a relief of 
difficulty swallowing and/or pain. Most patients suffered from at least one asso-
ciated symptom such as running nose or headache. About 40% of patients were 
advised to consult a physician especially when sore throat lasted longer or was 
associated to a higher number of concomitant symptoms. Combinations of anti-
septic and local anesthetic represent the most frequently advised product for sore 
throat in pharmacies. TROD were not currently offered in most pharmacies (86%) but 
2 pharmacists out of 3 consider delivering it in the future depending on adequate 
training and economic return. cOnclusiOns: The management of sore throat in 
pharmacies largely relies on over-the-counter medications. A wider availability of 
TROD could enable a better disease management and relevant referral to physicians 
in the case of bacterial involvement.
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Objectives: Tobacco consumption is a major public health concern. Every six 
seconds someone dies due to smoking and every second smoker will die from 
smoking-related disease. Smoking double the risk of cardiovascular morbidity and 
all-cause mortality, but smoking cessation significantly reduces this risk. In order to 
best target resources for intervention, this study identified subgroups in a generaliz-
able population who have the lowest smoking cessation rates. MethOds: This is a 
population-based retrospective observational study that assessed cessation rates 
among members of Clalit Health Services (Clalit), the largest health maintenance 
organization in Israel, who were aged 18 and older and reported that they were 
current smokers between 2010 and 2014. Results: There are about 642,000 Clalit 
members who reported that they were current smokers during the past between 
2010 and 2014 (consistent with the national rate of 21.1% in 2014). Of those 14.1% 
reported in 2014 that they quit smoking, versus 11.0% of the smokers reported that 
they had quit smoking in 2011. Cessation rates were lowest among women of certain 
age groups: 7.2% for those aged 18-21 and 13.8% for those aged 45-54 versus 19.9% 
for those aged 25-34, and 22.5% for those aged 65-74. Smokers from lower socioeco-
nomic status had lower smoking cessation rates compared to higher socioeconomic 
status (11.0% vs. 19.0%, respectively). cOnclusiOns: As of 2014, only one in seven 
currents smokers reports quitting and members from low socioeconomic status and 
young and midlife-age females have the lowest smoking cessation rates. Therefore, 
healthcare providers and smoking cessation interventions should consider focus 
on those populations.
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explore the cost implications of prescribing Ellipta portfolio in appropriate patients 
versus alternative therapies, in line with clinical guidelines. MethOds: a one-year 
BIM was constructed to explore financial implications of prescribing Ellipta medi-
cines as alternative treatment options to currently prescribed therapies. The BIM is 
based on UK prescription analysis, epidemiological and resource data. The BIM uses 
prescription data to generate patient cohorts and progresses them to more intensive 
therapy based on estimates of symptoms of exacerbation or breathlessness. It also 
considers medicines optimsation for patients that could benefit from simplified regi-
mens and estimates the budget impact of moving patients using non-licensed ICS/
LABA to licensed therapies. The model allows definition of treatment progressions, 
using appropriate Ellipta devices to target bronchodilator or steroid based regimens. 
Costs are calculated using market share of current treatments vs. a scenario in which 
Ellipta medicines are used. Differences in patient outcomes, efficacy or safety are not 
explored. Results: It is estimated that the average health economy in the UK has 
5,518 COPD patients of whom 1,320 are eligible to be progressed in their medication. 
In year 1, compared to a base case of utilising the most routinely used existing COPD 
therapies (100% implementation rate for new incident patients and 50% for all oth-
ers) would increase spend by £247,830 compared with a reduced budget impact of 
-£131,920 if these eligible patients were moved to Ellipta medicines. cOnclusiOns: 
The introduction of Ellipta portfolio in COPD could potentially reduce the budget 
impact and total spend on COPD therapies by £379,750 in the average UK health 
economy compared to current prescribing patterns. Funded by GSK
PRS21
BuDgET ImPACT AnALYSIS Of fORmOTEROL EASYhALER In ThE TREATmEnT 
Of ASThmA In ChILDREn In ThE RuSSIAn fEDERATIOn
Kulikov A, Kilimanova E
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct the budget impact analysis of Formoterol Easyhaler, which 
allowed to determine the net economic effect of the budget impact in regards of 
replacement of one medicine to another. MethOds: Information search was con-
ducted in the public domain. Pharmacoeconomic analysis method – budget impact 
and direct cost analysis were performed. Results: In this study, given the phar-
macoeconomic evaluation of drugs Formoterol Easyhaler, Oxis Turbuhaler, Foradil 
Aerolizer and Atimos. The study had a time horizon of one year. The daily dose of 
formoterol was 24 mcg. Cost analysis was conducted on the cost of basic phar-
macotherapy, compensation costs for treatment of exacerbations, compensation 
costs for side effects and adverse reactions. The total direct cost per patient with 
asthma amounted to 1 262, 17$ to the Easyhaler group, 1 581, 83$ to the Turbuhaler 
group, 1 498,95 and 1 499,99 to the Foradil (30 and 60 doses), and 1 705, 06$ to the 
Atimos. The selection of budget impact method of pharmacoeconomic analysis 
was determined by the advantages of Formoterol Easyhaler in terms of its effi-
ciency and lower value of total direct costs. In the present study, based on the 
results of the “cost analysis” it was revealed that the replacement formoterol of Oxis 
Turbuhaler, Foradil Aerolizer (30 and 60 doses) and Atimos on Easyhaler saved per 
patient respectively 319,66$, 236,78$ (187, 82$ for 60 doses) and 442,89$ for the health 
care system budget. cOnclusiOns: The budget impact analysis results obtained 
in this Formoterol Easyhaler versus others drugs of formoterol comparative study 
demonstrated that Easyhaler therapy resulted in budget saving.
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Objectives: Allergic rhinitis (AR) is a chronic disease of the upper respiratory tract 
caused by exposure to allergens inducing inflammation of the nasal mucosa and of 
the conjunctiva mediated by antibody Immunoglobulin E (IgE). According to local 
literature, prevalence of symptomatic AR is around 20% and grass pollen is the most 
common allergen causing A (%5 of uncontrolled moderate / severe AR) in Turkey. 
Allergen-specific immunotherapy (AIT) is recommended as a second line treatment 
for patients with moderate to severe allergic rhinitis not or poorly controlled by 
symptomatic treatments.The Five Grass Pollen Sublingual Tablet (5GPST) is an alter-
native AITin Turkey. The aim of this budget impact model (BIM) was to assess the 
cost saving potential of the 5GPST inthe Turkish reimbursement system. MethOds: 
Cost calculations were madefrom the payer perspective as per the guidelines of the 
Social Security Institution (SSI). The time horizon considered in the model was one 
year. The clinical data and Rescue Medication Scores were acquired from published 
clinical studies. Direct medical costs were considered in this analysis. Pricing and 
reimbursement prices data are obtained from Ministry of Health Drug Price List and 
the Price List of SSI Health Implementation Guideline. Results: According to the 
BIM, total cost of AR treatment for a patient treated with symptomatic treatment 
alone was 373 TL per year and reached 1.607 TL per year for patients receiving sub-
cutaneous immunotherapy. Total cost of AR with5GPSTwith %11discount for the first 
reimbursement year was 1.168 TL. Total yearly cost of AR with 5GPST with % 41 dis-
count was 864 TL. cOnclusiOns:: Compared to subcutaneous AIT, 5GPST is a cost 
saving alternative fortreatment of seasonal AR in Turkey from a SSI perspective. The 
treatment is 27% or 46% cheaper applying 11% or 41% discount rates respectively.
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mixed-treatment comparison) were applied at 2 weeks. Lung function decline after 
2 weeks was applied independent of treatment arm but dependant on GOLD stage. 
Exacerbation risk, health outcomes and costs of COPD management were calculated 
based on GOLD stage. Cost inputs were taken from published literature. Results: 
The 5-year budget impact of displacement of tiotropium by tiotropium + olodaterol 
Respimat®was a cost-saving of £25.8 million, £2.7 million, £1.6 million, and £0.9 
million, in England, Scotland, Wales, and Northern Ireland respectively. These 
cost-savings were largely driven by a predicted 0.8% reduction in COPD manage-
ment costs, and a predicted 0.9% reduction in the costs of exacerbation manage-
ment. cOnclusiOns: Switching patients with COPD from tiotropium maintenance 
to tiotropium + olodaterol Respimat® maintenance therapy has the potential to 
be cost-saving to the UK NHS. These cost-savings largely result from a predicted 
reduction in primary and secondary care costs. Whilst treatment switching should 
be driven by clinical rationale and patient preference, this finding has implications 
for medicine optimisation in the UK.
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Objectives: Spiriva® Handihaler® (tiotropium) is a single capsule dry powder 
inhaler (DPI) for the treatment of COPD. A budget impact model was developed 
to assess the potential economic impact of introducing an inhaler with improved 
features compared to Spiriva® Handihaler®to treat COPD in the UK. The potential 
cost benefit of increasing treatment satisfaction, due to the improved characteris-
tics of this new inhaler was investigated. MethOds: The eligible patient popula-
tion presented was based on the number of confirmed COPD diagnoses in the UK, 
with the proportion of patients receiving Spiriva® Handihaler® based on market 
research data. The costs of scheduled and unscheduled healthcare events presented 
within the model were taken from publically available UK sources. Findings from a 
multinational, cross-sectional, real-world survey of 1,443 COPD patients associat-
ing inhaler attributes, inhaler satisfaction, adherence and patient health status 
were used within the model to determine the correlations between inhaler sat-
isfaction, treatment adherence and unscheduled healthcare events. Using these 
correlations, an annual number of UK unscheduled healthcare events associated 
with COPD was calculated for patients using a new improved inhaler and Spiriva® 
HandiHaler®. Results: The annual UK costs of treating COPD patients for unsched-
uled healthcare events were € 1027.05 with Spiriva® HandiHaler®vs. € 922.14 with 
the new inhaler. Potential budgetary savings achieved by using the new inhaler 
instead of HandiHaler® were calculated at € 104.91 per patient and € 16.69 million 
for the UK COPD patient population per year. cOnclusiOns: There is a potential 
for a new improved tiotropium inhaler to offer budgetary savings compared with 
Spiriva® Handihaler® resulting from cost benefits due to increased patient satis-
faction with their inhaler.
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Objectives: This study estimated the total expenditure on prescribed Seasonal 
Allergic Conjunctivitis (SAC) medication in the UK and the budget impact of switch-
ing patients to alternative treatments. MethOds: A budget impact model devel-
oped from the UK NHS and Personal Social Services (PSS) perspective was used 
to evaluate total spending on: olopatadine, generic sodium cromoglicate, branded 
sodium cromoglicate, nedocromil sodium. A 4-month time horizon was applied 
(average allergy season duration). Direct to patient data (National Health and 
Wellness Survey [NHWS]) were used to estimate the number of patients receiving 
prescription SAC treatment. Published 42-day efficacy data were input for each 
product, with patients classified as either successfully treated or unsuccessfully 
treated at 14, 28, 42, and 120 days. Unsuccessful treatment required additional 
resource use and switch to further therapy. Two approaches extrapolated clinical 
data to 120 days: A) No decline after 42-days, B) linear decline in efficacy. Cost per 
treatment was estimated and multiplied by its market size to estimate the total 
current spend in the UK. Model structure and inputs were validated with clinical 
KOLs. Results: Under scenario A olopatadine treatment was associated with the 
lowest cost. Olopatadine spending over a four month period was £100.08 versus 
£104.39 for sodium cromoglicate. Under scenario B, sodium cromoglicate treatment 
resulted in costs of £114.97 versus £124.07 with olopatadine. An estimated 3,161,807 
UK adults are treated in the Rx market (NHWS). Total spending was estimated to 
exceed £300,000,000 under all scenarios. Under scenario A switching all patients 
to olopatadine may result in savings of £15,378,769. cOnclusiOns: Increasing 
olopatadine market share in SAC may be cost-saving when compared against alter-
native treatments for SAC. The use of direct to patient surveys are an important 
source in market sizing when considering markets split across prescription and 
over-the-counter treatments.
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Objectives: The GSK Ellipta portfolio medicines are licensed for treatment of COPD 
in the UK and is comprised of fluticasone furoate/vilanterol, umeclidinium bromide/
vilanterol and umeclidinium bromide. A budget impact model (BIM) was designed to 
